




In June 2022, most of the 29 oncology reports from five countries are expected to be published on the first, ninth and around the 22<sup>nd</sup> and 23<sup>rd</sup>.



16 out of 28 assessments (57%) are expected in lung and breast cancer as well multiple myeloma with France and the UK having scheduled 9 and 8 SDAs respectively



For reference, in May 2022, 21 out of 29 SDAs in the same disease areas were largely positive or with restrictive conditions



- 29 SDAs in 7 countries (Denmark, France, Germany, Poland, Spain, Sweden, UK) were published in oncology in May 2022.
- 72% (21 out of 29 assessments) were positive or with restrictive conditions.
- 6 out of 8 assessments (75%) with negative recommendations came from Spain due to *insufficient or uncertain clinical benefit*.

Source: IQVIA HTA Accelerator.

All ongoing SDAs in oncology with expected publication date from 1 June 2022 till 30 June 2022. For reference: all SDAs in oncology with publication date from 1 May 2022 till 31 May 2022.

This analysis includes only reports with clear positive, restricted/conditioned or negative recommendations; Positive recommendation = The technology has been recommended without any restrictions to the full licensed indication. Restricted/Conditioned = The technology has been recommended but with restrictions to specific patient populations; Negative recommendation = The technology has not been recommended

Abbreviations: HTA = Health technology assessment; SDA = Single drug assessment